On the other hand, radiolabeled SSTR2-antagonists exhibit improved pharmacokinetic properties and can offer promising novel therapeutic options 14, bearing the potential of improved response rates because of increased tumor uptake and longer residence times 40. This evidence concerns the gene SSTR2 and neoplasm.